Literature DB >> 17697831

Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide.

Heidi T May1, Benjamin D Horne, Wayne C Levy, Abdallah G Kfoury, Kismet D Rasmusson, David T Linker, Dariush Mozaffarian, Jeffrey L Anderson, Dale G Renlund.   

Abstract

Management of heart failure (HF) remains complex with low 5-year survival. The Seattle Heart Failure Model (SHFM) is a recently described risk score derived predominantly from clinical trial populations that may enable the prediction of survival in patients with HF. This study sought to validate the SHFM in an independent, nonclinical trial-based HF population. Patients (n = 4,077) from the hospital-based Intermountain Heart Collaborative Study registry with a diagnosis of HF were evaluated using prospectively collected data (mean +/- SD follow-up 4.4 +/- 3.1 years). The SHFM was used to calculate a risk score for each patient. Receiver-operating characteristic area under the curve provided SHFM predictive ability for a composite end point of survival free from death, transplantation, or left ventricular assist device implantation. Addition of creatinine, serum urea nitrogen, diabetes status, and B-type natriuretic peptide (BNP) to the SHFM was also evaluated. Patient age averaged 67 +/- 13 years and 61% were men. Area under the curves were 0.70 (95% confidence interval 0.66 to 0.70), 0.67 (95% confidence interval 0.66 to 0.69), 0.67 (95% confidence interval 0.065 to 0.68), and 0.66 (95% confidence interval 0.63 to 0.67) for 1-, 2-, 3-, and 5-year survivals, respectively. Area under the curves were slightly attenuated in patients >75 years of age (n = 1,339), implantable cardioverter-defibrillator recipients (n = 693), and patients with an ejection fraction >40% (n = 1,634). BNP added significantly to the model (area under the curve +0.06). BNP was found to add additional predictive ability at 1 year (area under the curve change +0.05) and nominally at 5 years (area under the curve change +0.02). In conclusion, the SHFM predicts survival in patients with HF in a hospital-based population, with areas under the curve similar to those from data on which models were initially fit.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17697831     DOI: 10.1016/j.amjcard.2007.03.083

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

Review 1.  [Percutaneous aortic valve replacement - pro].

Authors:  Lutz Buellesfeld; Eberhard Grube
Journal:  Herz       Date:  2009-03       Impact factor: 1.443

2.  An Appraisal of Biomarker-Based Risk-Scoring Models in Chronic Heart Failure: Which One Is Best?

Authors:  Barbara S Doumouras; Douglas S Lee; Wayne C Levy; Ana C Alba
Journal:  Curr Heart Fail Rep       Date:  2018-02

Review 3.  Prediction of mortality in patients with heart failure and systolic dysfunction.

Authors:  Wayne C Levy; David T Linker
Journal:  Curr Cardiol Rep       Date:  2008-05       Impact factor: 2.931

4.  A key role for nuclear cardiac imaging in evaluating and managing patients with heart failure.

Authors:  Mark I Travin; Gayathri Kamalakkannan
Journal:  J Nucl Cardiol       Date:  2012-10       Impact factor: 5.952

5.  New predictive models of heart failure mortality using time-series measurements and ensemble models.

Authors:  Devika Subramanian; Venkataraman Subramanian; Anita Deswal; Douglas L Mann
Journal:  Circ Heart Fail       Date:  2011-05-11       Impact factor: 8.790

6.  Impact of prolonged utilization of neprilysin inhibition on the cognitive function of heart failure patients.

Authors:  Niel N Shah; Muhammad U Dogar; Parin N Shah; Sameera Ishtiaq; Shawn Mathew; Pratik Shah; Alia Ishtiaq; Timothy J Vittorio
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-03-13

Review 7.  Current indications for transplantation: stratification of severe heart failure and shared decision-making.

Authors:  Darko Vucicevic; Lily Honoris; Federica Raia; Mario Deng
Journal:  Ann Cardiothorac Surg       Date:  2018-01

8.  Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure.

Authors:  Larry A Allen; Jonathan E Yager; Michele Jonsson Funk; Wayne C Levy; James A Tulsky; Margaret T Bowers; Gwen C Dodson; Christopher M O'Connor; G Michael Felker
Journal:  JAMA       Date:  2008-06-04       Impact factor: 56.272

9.  From statistical significance to clinical relevance: A simple algorithm to integrate brain natriuretic peptide and the Seattle Heart Failure Model for risk stratification in heart failure.

Authors:  Omar F AbouEzzeddine; Benjamin French; Sultan A Mirzoyev; Allan S Jaffe; Wayne C Levy; James C Fang; Nancy K Sweitzer; Thomas P Cappola; Margaret M Redfield
Journal:  J Heart Lung Transplant       Date:  2016-01-15       Impact factor: 10.247

10.  Associations between seattle heart failure model scores and medical resource use and costs: findings from HF-ACTION.

Authors:  Yanhong Li; Wayne C Levy; Matthew P Neilson; Stephen J Ellis; David J Whellan; Kevin A Schulman; Christopher M O'Connor; Shelby D Reed
Journal:  J Card Fail       Date:  2014-06-02       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.